This review outlines the pathophysiology and management of placental insufficiency, emphasizing dipyridamole as the preferred antiplatelet therapy during pregnancy.
Answers are grounded in this paper and cite their sources.
May support dipyridamole preference in placental insufficiency; leaves open need for randomized confirmation.
Placental insufficiency is an acute or chronic process leading to progressive deterioration in placental function and a decrease in transplacental transfer of oxygen and nutrients to the fetus. The resulting fetal hypoxemia is hypoxia and reduction in fetal growth with abnormal neurodevelopment during childhood as outcome. Current approaches in classification, diagnostics and management of placental insufficiency in women with complicated pregnancy are presented in the review article. Treatment of placental insufficiency includes antiplatelet agents, low molecular weight heparins and vitamin and mineral supplementation. Dipyridamole is most preferred antiplatelet agents that could be prescribed in I-III trimesters. Proper preconception can help to prevent placental insufficiency in women with respective risk-factors.
No takes yet. Share an insight, caveat, or question.
Makatsariya et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: